在一组肾移植受者中对44个报告的与他克莫司谷浓度相关的单核苷酸多态性（SNP）进行验证尝试。
Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.
作者信息
Oetting William S, Wu Baolin, Schladt David P, Guan Weihua, Remmel Rory P, Dorr Casey, Mannon Roslyn B, Matas Arthur J, Israni Ajay K, Jacobson Pamala A
机构信息
Department of Experimental & Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Department of Biostatistics, University of Minnesota, Minneapolis, MN 55455, USA.
出版信息
Pharmacogenomics. 2018 Feb;19(3):175-184. doi: 10.2217/pgs-2017-0187. Epub 2018 Jan 10.
Abstract
AIM
Multiple genetic variants have been associated with variation in tacrolimus (TAC) trough concentrations. Unfortunately, additional studies do not confirm these associations, leading one to question if a reported association is accurate and reliable. We attempted to validate 44 published variants associated with TAC trough concentrations.
MATERIALS & METHODS: Genotypes of the variants in our cohort of 1923 kidney allograft recipients were associated with TAC trough concentrations.
RESULTS
Only variants in CYP3A4 and CYP3A5 were significantly associated with variation in TAC trough concentrations in our validation.
CONCLUSION
There is no evidence that common variants outside the CYP3A4 and CYP3A5 loci are associated with variation in TAC trough concentrations. In the future rare variants may be important and identified using DNA sequencing.
摘要
目的
多种基因变异与他克莫司（TAC）谷浓度的变化有关。遗憾的是，后续研究并未证实这些关联，这让人质疑所报道的关联是否准确可靠。我们试图验证44个已发表的与TAC谷浓度相关的变异。
材料与方法
在我们1923例肾移植受者队列中，这些变异的基因型与TAC谷浓度相关。
结果
在我们的验证中，只有CYP3A4和CYP3A5中的变异与TAC谷浓度的变化显著相关。
结论
没有证据表明CYP3A4和CYP3A5基因座以外的常见变异与TAC谷浓度的变化有关。未来，罕见变异可能很重要，可通过DNA测序进行识别。
相似文献
1
Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.在一组肾移植受者中对44个报告的与他克莫司谷浓度相关的单核苷酸多态性（SNP）进行验证尝试。
Pharmacogenomics. 2018 Feb;19(3):175-184. doi: 10.2217/pgs-2017-0187. Epub 2018 Jan 10.
2
Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.非裔美国肾移植受者中他克莫司浓度的全基因组关联研究确定了多个CYP3A5等位基因。
Am J Transplant. 2016 Feb;16(2):574-82. doi: 10.1111/ajt.13495. Epub 2015 Oct 20.
3
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.全基因组关联研究确定了CYP3A4和CYP3A5中的常见变异体，这些变异体导致了白种人肾移植受者中他克莫司谷浓度的差异。
Pharmacogenomics J. 2018 May 22;18(3):501-505. doi: 10.1038/tpj.2017.49. Epub 2017 Nov 21.
4
Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.他克莫司谷值和剂量的个体内变异性与 CYP3A5 基因型：对欧洲裔美国人和非裔美国人肾移植受者急性排斥反应和移植物失功的影响。
Clin Transplant. 2018 Dec;32(12):e13424. doi: 10.1111/ctr.13424. Epub 2018 Oct 31.
5
Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.北卡罗来纳州东部肾移植受者 CYP3A5 基因组变异及其对他克莫司剂量需求的影响的流行率。
Pharmacotherapy. 2017 Sep;37(9):1081-1088. doi: 10.1002/phar.1970. Epub 2017 Jul 27.
6
The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.白细胞介素-10 和 CYP3A5 基因多态性对肾移植后早期患者血他克莫司谷浓度的影响。
Pharmacol Rep. 2021 Oct;73(5):1418-1426. doi: 10.1007/s43440-021-00288-2. Epub 2021 Jun 5.
7
A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.寻找新的 CYP3A4 变体作为肾移植患者他克莫司剂量需求的决定因素。
Pharmacogenet Genomics. 2013 Aug;23(8):445-8. doi: 10.1097/FPC.0b013e3283636856.
8
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.新型与他克莫司谷浓度相关的多态性：来自一个多中心肾脏移植联盟的结果。
Transplantation. 2011 Feb 15;91(3):300-8. doi: 10.1097/TP.0b013e318200e991.
9
Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.CYP3A5基因多态性对接受不同剂型他克莫司的日本肾移植受者剂量校正谷浓度分布及排斥反应发生率的影响。
Clin Exp Nephrol. 2017 Oct;21(5):787-796. doi: 10.1007/s10157-016-1375-4. Epub 2017 Mar 7.
10
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.CYP3A4*22和CYP3A5*3单核苷酸多态性的组合决定肾移植后他克莫司的剂量需求。
Pharmacogenet Genomics. 2017 Sep;27(9):313-322. doi: 10.1097/FPC.0000000000000296.
引用本文的文献
1
Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort.肾移植患者队列中药物遗传学与长期临床进展的关联。
Curr Res Pharmacol Drug Discov. 2025 Jul 24;9:100230. doi: 10.1016/j.crphar.2025.100230. eCollection 2025.
2
Polymorphisms in , and genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients-a systematic review.、和基因的多态性：对造血细胞移植受者钙调神经磷酸酶抑制剂治疗的影响——一项系统综述
Front Pharmacol. 2025 Jul 16;16:1569353. doi: 10.3389/fphar.2025.1569353. eCollection 2025.
3
Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.揭示沙特人群中选定的未探索药物遗传标记的遗传力。
Front Pharmacol. 2025 May 1;16:1559399. doi: 10.3389/fphar.2025.1559399. eCollection 2025.
4
Impact of and genetic variants on tacrolimus dosing in Greek kidney transplant recipients.[具体基因名称]和[具体基因名称]基因变异对希腊肾移植受者他克莫司给药剂量的影响。
Front Pharmacol. 2025 Mar 19;16:1538432. doi: 10.3389/fphar.2025.1538432. eCollection 2025.
5
Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.他克莫司药代动力学受 CYP3A5、年龄和氟康唑伴随用药的影响，在儿科肾移植患者中。
Clin Transl Sci. 2023 Oct;16(10):1768-1778. doi: 10.1111/cts.13571. Epub 2023 Jun 26.
6
Evaluation of limited-sampling strategies to calculate AUC and the role of in Chilean pediatric kidney recipients using extended-release tacrolimus.评估用于计算曲线下面积（AUC）的有限采样策略以及缓释他克莫司在智利儿科肾移植受者中的作用。
Front Pharmacol. 2023 Mar 14;14:1044050. doi: 10.3389/fphar.2023.1044050. eCollection 2023.
7
Association between rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults.rs2235048基因多态性与年轻成年人吸食大麻后的四氢大麻酚药代动力学及主观效应之间的关联
Brain Sci. 2022 Sep 3;12(9):1189. doi: 10.3390/brainsci12091189.
8
Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients.影响他克莫司代谢的基因多态性及其与肾移植受者移植后结局的关系
Pharmgenomics Pers Med. 2021 Nov 19;14:1463-1474. doi: 10.2147/PGPM.S337947. eCollection 2021.
9
The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.白细胞介素-10 和 CYP3A5 基因多态性对肾移植后早期患者血他克莫司谷浓度的影响。
Pharmacol Rep. 2021 Oct;73(5):1418-1426. doi: 10.1007/s43440-021-00288-2. Epub 2021 Jun 5.
10
CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.CYP3A5和UGT1A9基因多态性对小儿肾移植受者免疫抑制治疗的影响。
Front Pharmacol. 2021 Apr 22;12:653525. doi: 10.3389/fphar.2021.653525. eCollection 2021.
本文引用的文献
1
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.全基因组关联研究确定了CYP3A4和CYP3A5中的常见变异体，这些变异体导致了白种人肾移植受者中他克莫司谷浓度的差异。
Pharmacogenomics J. 2018 May 22;18(3):501-505. doi: 10.1038/tpj.2017.49. Epub 2017 Nov 21.
2
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.高他克莫司清除率是肾移植术后早期急性排斥反应的一个危险因素。
Transplantation. 2017 Aug;101(8):e273-e279. doi: 10.1097/TP.0000000000001796.
3
IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.白细胞介素-3和细胞毒性T淋巴细胞相关抗原4基因多态性可能影响中国肾移植受者的他克莫司剂量需求。
Acta Pharmacol Sin. 2017 Mar;38(3):415-423. doi: 10.1038/aps.2016.153. Epub 2017 Jan 23.
4
Validation Is Critical for Genome-Wide Association Study-Based Associations.验证对于基于全基因组关联研究的关联至关重要。
Am J Transplant. 2017 Feb;17(2):318-319. doi: 10.1111/ajt.14051. Epub 2016 Oct 12.
5
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.基于高通量基因筛查的他克莫司剂量需求预测模型
Am J Transplant. 2017 Apr;17(4):1008-1019. doi: 10.1111/ajt.14040. Epub 2016 Oct 7.
6
Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.CYP3A4/5基因评分和ABCB1基因多态性对巴西肾移植患者他克莫司血药浓度及肾功能的影响。
Pharmacogenet Genomics. 2016 Oct;26(10):462-72. doi: 10.1097/FPC.0000000000000237.
7
Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.CYP3A4和CYP3A5基因多态性对肾移植受者他克莫司剂量的影响
Iran J Kidney Dis. 2016 May;10(3):156-63.
8
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.他克莫司在肾移植中应用的药物遗传学方面：最新进展及种族因素考量
Expert Opin Drug Metab Toxicol. 2016 May;12(5):555-65. doi: 10.1517/17425255.2016.1170808. Epub 2016 Apr 7.
9
Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients.CYP3A5基因多态性对肾移植受者他克莫司药代动力学的影响
Transplant Proc. 2016 Jan-Feb;48(1):81-7. doi: 10.1016/j.transproceed.2016.01.001.
10
A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET Plus platform.一项使用DMET Plus平台对健康受试者中他克莫司药代动力学进行的药物基因组学研究。
Pharmacogenomics J. 2017 Mar;17(2):174-179. doi: 10.1038/tpj.2015.99. Epub 2016 Feb 16.
Zotero 插件